mavacamten (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Obstructive Hypertrophic Cardiomyopathy

Pending FDA approval for patients aged ≥18 years with symptomatic obstructive hypertrophic cardiomyopathy

Next:

Pharmacology

Mechanism of Action

Selective allosteric inhibitor of cardiac myosin ATPase to reduce actin–myosin cross-bridge formation

This action targets the underlying sarcomere, the basic contractile unit of striated muscle, and thereby reduces contractility and improves myocardial compliance

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.